

Special Publication No. 42

---

## The Chemical Regulation of Biological Mechanisms

---

The Proceedings of the 1st Medicinal Chemistry Symposium,  
organised by the Fine Chemicals and Medicinals Group of the  
Industrial Division of the Royal Society of Chemistry and  
the Fine Chemicals Group of the Society of Chemical  
Industry

Cambridge, England, 27th—30th September 1981

Edited by  
**A. M. Creighton**  
Imperial Cancer Research Fund, London

**S. Turner**  
Polytechnic of North London

The Royal Society of Chemistry  
Burlington House, London W1V 0BN

---



The joint organising committee for the Symposium comprised:

- Dr. D.E. Bays (Glaxo Group Research Ltd.)
- Dr. F.C. Copp (The Wellcome Research Laboratories)
- Dr. A.M. Creighton (Imperial Cancer Research Fund Laboratories)
- Dr. G.J. Durant (Smith Kline & French Research Ltd.)
- Dr. J.C. Emmett (Smith Kline & French Research Ltd.)
- Dr. W.J. Ross (Lilly Research Centre Ltd.)
- Dr. S. Turner (Polytechnic of North London)

## Contents

<b>Histamine</b>	
Characterisation and Distribution of Histamine Receptors	1
By C.E. Ganellin	
Biochemical Mechanisms of Action of Histamine	16
By C.L. Johnson	
Some Structure-Activity Considerations in H <sub>2</sub> -Receptor Antagonists	27
By T.E. Brown, G.J. Durant, J.C. Essett, C.E. Ganellin, H.D. Prain and S.C. Young	
Aminoalkylfurans as H <sub>2</sub> -Receptor Antagonists	45
By J. Bradshaw, M.E. Butcher, J.W. Clitheroe, M.D. Doule, S. Hayes, D.E. Judd, J.M. McKinnon, and E.J. Price	
2-Guanidinothiazoles as H <sub>2</sub> -Receptor Antagonists	58
By R.J. Gilman, D.F. Jones, K. Oldham, J.M. Wardlaworth, and F.O. Tellin	
<b>GABA</b>	
Do Benzodiazepines Act through a GABA-ergic Mechanism?	77
By E. Costa	
GABA Agonists: Chemical, Molecular Pharmacological, and Therapeutic Aspects	92
By P. Espgaard-Larsen, P. Jacobsen, E. Falck, and H. Hvide	
GABA-Related Pro-Drugs	112
By C.-G. Wernth, A. Zincane, J.J. Bourguignon, and J.P. Charbon	
<b>Dopamine</b>	
Dopamine Receptor Manipulation, with Special Reference to Autoreceptors	132
By L.-E. Aroldsson, A. Carlsson, U. Hansell, S. Hjorth, P. Lindberg, J.L.G. Nilsson, D. Smolke, U. Swansson, and A. Wikström	

Substituted Benzamides as Dopamine Antagonists <i>By M.S. Hadley</i>	140
Interactions of Chiral Agonists with Dopamine Receptors <i>By H.S. Fraenkel and J.D. McDermid</i>	154
Dopaminergic Agents Related to Ergolines <i>By J.A. Clavens, E.C. Kornfeld, L.A. Phelan, C.J. Sharr, E.B. Skala Wg, J.M. Cassidy, D.E. Nichols, E.G. Foose, and E. Kelly</i>	167
Opiate Receptors	
Highly Selective Affinity Labels for the Investigation of Opioid Receptor Subtypes <i>By P.S. Portoghesi and A.E. Takemori</i>	181
Stereoelectronic Regulation of the Opiate Receptor: Some Conceptual Problems <i>By S. Bellan</i>	200
Recent Developments in Analgesic Research: Opiate Action at Multiple Receptors <i>By M.J. Sance</i>	222
The Chemistry and Pharmacology of Opioid Peptides <i>By T.W. Smith and S. Wilkinson</i>	230
Regulatory Peptides	
Peptidergic Receptors as Targets for Drug Action: Biochemical Pharmacology of Substance P <i>By M. Bradley, L. Iversen, S. Iversen, C. Lee, B. Smedberg, and S. Watson</i>	255
Delivery of Regulatory Peptides <i>By G.J. Dockray and C. Villant</i>	267
Conformational Studies of Peptide Hormones as a Basis for Analog Design <i>By G.R. Marshall</i>	279
Selectivity and Antagonism in Analogues of Regulatory Peptides <i>By J.S. Morley</i>	293
Peptide Analog Design Based on Conformation <i>By D.P. Weber</i>	309